Recombinant Human CD160 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human CD160 protein (rFc Tag) (Eg1719)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1719

---

Validation Data Gallery

• 

  Purity of Recombinant Human CD160 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CD160 protein Ile27-Ser159 (Accession# O95971-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 11126
• Accession: O95971-1
• PredictedSize: 41.1 kDa
• SDS-PAGE: 44-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD160 is a glycosylphosphatidylinositol (GPI)-anchored protein that is expressed on almost all intestinal intraepithelial lymphocytes (IELs), gamma delta T cells, CD56 (dim) CD16+ cytotoxic NK cells, and a minor subset of CD4+ and CD8+ T cells. The binding of CD160 to both classical and non-classical MHC I enhances NK and CD8+ cytotoxic T lymphocyte functions. CD160 is a ligand for HVEM (herpes virus entry mediator) and the binding of CD160 to HVEM inhibits T cell activity.

References:

1. Tae-Jin Kim, et al. (2019). Nat Commun.10(1):3258.
2. Mohamed El-Far, et al.(2014). J Transl Med.12:217.
3. Guifang Cai, et al.(2009). Immunol Rev. 229(1):244-58.